Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia

SIMPLE SUMMARY: Tyrosine kinase inhibitors (TKIs), such as imatinib, have become the standard initial treatment of choice for chronic myeloid leukemia (CML) patients. However, one obstacle to face is that a significant proportion of patients presents poor response to TKIs, or acquires resistance res...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostazo, Miriam G. Contreras, Kurrle, Nina, Casado, Marta, Fuhrmann, Dominik, Alshamleh, Islam, Häupl, Björn, Martín-Sanz, Paloma, Brüne, Bernhard, Serve, Hubert, Schwalbe, Harald, Schnütgen, Frank, Marin, Silvia, Cascante, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699488/
https://www.ncbi.nlm.nih.gov/pubmed/33228196
http://dx.doi.org/10.3390/cancers12113443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699488/
https://www.ncbi.nlm.nih.gov/pubmed/33228196
http://dx.doi.org/10.3390/cancers12113443

Ejemplares similares